CN1424313A - Chuanxiong alkoxide derivative and its preparation and medicinal composition containing it and use thereof - Google Patents
Chuanxiong alkoxide derivative and its preparation and medicinal composition containing it and use thereof Download PDFInfo
- Publication number
- CN1424313A CN1424313A CN 02135989 CN02135989A CN1424313A CN 1424313 A CN1424313 A CN 1424313A CN 02135989 CN02135989 CN 02135989 CN 02135989 A CN02135989 A CN 02135989A CN 1424313 A CN1424313 A CN 1424313A
- Authority
- CN
- China
- Prior art keywords
- acid
- ligusticum wallichii
- preparation
- alkoxide
- alkoxide derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
A cindium alkoxide derivative is prepared from its intermediate 2-hydroxymethyl-3,5,6-trimethyl pyrazine through dewatering synthesis method where N,N-bimethylamino pyridine is used as catalyst and the organic carboxylic acid and dicyclohexyl hypoacylurea also take part in reaction, or through acylation synthesis method where organic carboxylic acid and sulfoxide are used to prepare acid chloride and then take part in acylation synthesis along with pyridine, and the product is separated and purified. Its medicinal composition can be used to repair or protect the vascular endothelial cells or as endothelin receptor antagon.
Description
(1) technical field
The present invention relates to a kind of derivative and preparation method thereof and medicinal application, be specifically related to Ligusticum wallichii alkoxide derivative and preparation method thereof, and this derivative and assistant agent are formed pharmaceutical composition, belong to the derivative drugs technical field.
(2) background technology
Cardiovascular and cerebrovascular diseases is common disease, the frequently-occurring disease that human health in serious harm, along with social population aging, sickness rate rises day by day.Data shows that because of the death that cardiovascular and cerebrovascular diseases caused has surpassed 50% of the total cause of the death of population, the World Health Organization classifies cardiovascular and cerebrovascular diseases as " the sanitarian dead enemy in the world ".The medicine that is used for the treatment of at present cardiovascular and cerebrovascular diseases clinically is more, but shortcoming such as ubiquity poor selectivity, toxic side effect be bigger.Therefore, seek cardiovascular and cerebrovascular diseases medicine efficient, low toxicity and be still one of emphasis of drug research.
Ligusticum wallichii (Ligusticum Wallichii Franch) is the dry rhizome of samphire Ligusticum wallichii, it is the motherland medical practice proof first place evident in efficacy traditional plant medicine that activates blood circulation and disperses blood clots, have activate blood circulation and disperse blood clots, the effect of promoting the circulation of qi analgesic therapy, be widely used in the treatment of the acute and chronic ischemia heart, cerebrovascular disease, its main active ingredient is Ligusticum wallichii alkaloids such as Ligustrazine.
Ligustrazine (Ligustrazine), different name Ligustrazine I alkali, the chemical name 2, the abbreviation tetramethylpyrazine (Tetramethylyrazine, TMP), the structure See Figure:.
Pharmacological research proves: TMP has vasodilation, suppresses the vascular smooth muscle contraction, increases coronary blood flow and microcirculation improvement effect; Can reduce surface activity of blood platelet, blood viscosity lowering has restraining effect to platelet aggregation, and accumulative thrombocyte is had unzipping, referring to often rendering meritorious service Yue Yili etc. Chinese Medical Sciences University's journal, 1992,9:196; Wu Guoxin is Jin Chang etc., Acta Pharmacologica Sinica, 1992,13:330; In addition, it has provide protection to the hypoxic-ischemic cardiac muscle, is considered to one novel " calcium ion antagonist ", translates foreign medical science-plant amedica fascicle 1997,12:881 referring to Xu Ruming.
Ligustrazine shows that at the intravital pharmacokinetic parameter of people oral phosphoric acid Ligustrazine reaches the highest Plasma Concentration 3.114 ± 0.902 μ g/ml about 30 minutes, and medicine is described, and the absorption rate ratio is very fast in vivo; Transformation period is 0.486 ± 0.188h, total apparent distribution volume is 66.77L, illustrates that TMP is distributed more widely in vivo, and the rapid metabolism of medicine is simultaneously eliminated, the elimination transformation period is 2.894 ± 0.558h, 3h after the administration, the TMP Plasma Concentration is reduced to 0.5 μ g/ml, referring to Cai Wei, Dong Shannian etc., Acta Pharmaceutica Sinica, 1993,15:79.Because the transformation period is short in vivo, bioavailability is lower for TMP, need frequent drug administration for guaranteeing curative effect, easy toxigenicity, the result still can not be satisfactory.Therefore, be lead compound with the Ligustrazine, carry out structure of modification and optimization, improve its pharmacokinetic parameter, development and development of new Ligustrazine class cardiovascular and cerebrovascular diseases medicine efficient, low toxicity is had great importance.
The basic reason that Ligustrazine is eliminated soon in vivo, the transformation period is short is that the methyl in the Tetramethylpyrazine molecule is easy to oxidized, generate polarity and water-soluble bigger meta-bolites 2-methylol-3,5,6-trimethylpyrazine (Ligusticum wallichii alcohol) and excreting rapidly, referring to Chen Xin, Dong Shannian. Acta Pharmaceutica Sinica, 1996,31:617; With the river thoroughbred horse, Jiang Guohui etc., Chinese Academy of Medical Sciences's journal, 1996,18:228.
(3) summary of the invention
The present invention is directed to the deficiencies in the prior art, a kind of Ligusticum wallichii alkoxide derivative and preparation method thereof and the pharmaceutical composition and the application that contain Ligusticum wallichii alkoxide derivative are provided.
Technical scheme of the present invention is as follows: 1. Ligusticum wallichii alkoxide derivative
According to the collaborative principle of biological activity, introduce the active drug group.Promptly on Ligustrazine meta-bolites Ligusticum wallichii alcohol-2 methylol, introduce acetyl salicyloyl, nicotinoyl, to chlorobenzene oxygen isobutyryl, asafoetide carboxyl groups.
Introducing aromatic group can increase the fat-soluble of drug molecule, makes medicine be easy to permeate through cell membranes.Promptly aromatic nucleus is carried out different replacements as introducing halogen atom, methoxyl group and insert saturated, unsaturated carbon chains between phenyl ring and carbonyl, substituting group position and number have certain influence to pharmaceutical activity.
Ligusticum wallichii alkoxide derivative of the present invention has following general structure:
Wherein R is phenyl, monosubstituted phenyl or polysubstituted phenyl; Benzyl, the single replacement or polysubstituted benzyl; Styroyl, the single replacement or polysubstituted styroyl; Styryl, the single replacement or polysubstituted styryl; The substituted benzene oxygen ethyl; Five-membered ring or substituted five-membered heterocycle, hexa-member heterocycle or replacement hexa-member heterocycle; Amino acid based.
Above-mentioned heterocycle is meant fat or aromatic heterocycle.2. the synthetic route of Ligusticum wallichii alkoxide derivative is as follows:
3. the 2-methylol-3,5 of Ligusticum wallichii alkoxide derivative, 6-trimethylpyrazine (IV) intermediate and preparation
The intermediate of Ligusticum wallichii alkoxide derivative is the 2-methylol-3,5 with above-mentioned IV structure, the 6-trimethylpyrazine.The preparation method is as follows:
(1) Tetramethylpyrazine trihydrate, Glacial acetic acid and 30% hydrogen peroxide were mixed by weight 3: 4: 1.5, in 70～80 ℃ of reacting by heating 4～5 hours, add 30% hydrogen peroxide of equivalent, continue reaction 4～5 hours, thin-layer chromatography (TLC) monitoring is cooled to room temperature to reacting completely;
(2) regulate PH=10, chloroform extraction, anhydrous Na with 45%～60% sodium hydroxide solution
2SO
4Drying is filtered, and boils off trichloromethane, obtains Ligustrazine list oxynitrides crude product;
(3) add aceticanhydride then, reflux 2～3 hours, TLC monitoring removes excessive aceticanhydride under reduced pressure after react completely, and obtains black pulpous state Ligustrazine acetylate;
(4) the cooling back adds 20%～30% sodium hydroxide solution, places ethyl acetate extraction, anhydrous Na 10～20 hours
2SO
4Drying is filtered, and removes solvent under reduced pressure, obtains 2-methylol-3,5,6-trimethylpyrazine (IV) intermediate.
(5), get yellow needle crystal with sherwood oil (30-60 ℃) recrystallization.4. the preparation method of Ligusticum wallichii alkoxide derivative
The preparation method of Ligusticum wallichii alkoxide derivative; comprise with above-mentioned intermediate 2-methylol-3; 5; 6-trimethylpyrazine (IV) and organic carboxyl acid are at N; the inferior uride of dicyclohexyl under N dimethylamine yl pyridines (DMAP) catalysis (DCC) dehydration synthesis method or by organic carboxyl acid and sulfur oxychloride being made the acidylate synthesis method under pyridine alkalescence behind the acyl chlorides, then through separate, the purifying acquisition.(1) synthetic, press one of following method: 1. inferior uride (DCC) evaporation of dicyclohexyl is synthetic
With above-mentioned 2-methylol-3,5,6-trimethylpyrazine intermediate, organic carboxyl acid and N, N dimethylamine yl pyridines (DMAP) is pressed mmole (mmol) and is mixed than 1～2: 2～4: 0.1～0.2, add 10～15ml pyridine, dissolving adds the inferior uride of dicyclohexyl (DCC) and equates mmole amount (mmol) with organic carboxyl acid, white precipitate dicyclohexylurea (DCU) (DCU) appears, stirring at room 20～30 hours.After the TLC monitoring reaction reached balance, stopped reaction filtered and removes white DCU precipitation, and filtrate adds 2～3g silica gel evaporated under reduced pressure.Mixture purifying to be separated.2. chloride method is synthetic
Dripping thionyl chloride 0.8～0.9ml and pyridine 0.25ml remove ice bath under organic carboxyl acid 8～9mmol condition of ice bath, slowly are warming up to and boil, back flow reaction 2～3 hours.TLC monitoring is after react completely, and cooling removes excessive sulfur oxychloride under reduced pressure, and residue adds 12～16ml tetrahydrofuran (THF) and fully stirs, and obtains the tetrahydrofuran solution of organic carboxyl acid acyl chlorides.Under condition of ice bath, above-mentioned organic carboxyl acid solution of acid chloride joined contain 2-methylol-3,5, in the tetrahydrofuran solution of 6-trimethylpyrazine and pyridine, remove ice bath, heating reflux reaction 3～4 hours.TLC monitoring is after react completely, and cooling removes by filter pyridinium salt, and filtrate decompression is steamed and removed tetrahydrofuran (THF).Mixture purifying to be separated.(2) 1. rapid column chromatography separation of separation and purification, the eluting solvent system is: cyclohexane/ethyl acetate.Get Ligusticum wallichii alkoxide derivative.2. also can directly get Ligusticum wallichii alkoxide derivative 2-and replace acyl-oxygen methyl-3,5, the crystallization of 6-trimethylpyrazine with the organic solvent recrystallization method.
Above-mentioned organic carboxyl acid is: phenylformic acid, the single replacement or polysubstituted phenylformic acid; Toluylic acid, the single replacement or polysubstituted toluylic acid; Phenylpropionic acid, the single replacement or polysubstituted benzo acid; Styracin or various substituted cinnamic acid; Bezalip Tablets or various substituted benzene oxygen isopropylformic acid; Each seed amino acid; Various alicyclic heterocyclics or fragrant heterocyclic carboxylic acid and various replacement alicyclic heterocyclic or fragrant heterocyclic carboxylic acid.
Above-mentioned organic solvent is: the mixed solvent of tetracol phenixin, normal hexane, hexyl acetate, hexanaphthene/hexyl acetate arbitrary proportion.The structure of table 1 partial synthesis compound
No. R No. R
5. Ligusticum wallichii alkoxide derivatives medicinal composition
Ligusticum wallichii alkoxide derivatives medicinal composition of the present invention contains above-mentioned Ligusticum wallichii alkoxide derivative, and Ligusticum wallichii alkoxide derivative and auxiliary material be mixed routinely, makes the medicine of different dosage form according to a conventional method.6. the application of rhizome of chuanxiong alkoxide derivatives medicinal composition
Ligusticum wallichii alkoxide derivatives medicinal composition is used for the reparation and protection medicine of vascular endothelial cell (VECs), and endothelin-receptor antagonists.(1) Ligusticum wallichii alkoxide derivative is to the influence of normal people's huve cell (HUVECs) propagation.
Atherosclerotic initiating agent is not only in vascular endothelial cell (VECs) damage, and advancings of disease such as coronary heart disease, hypertension are played an important role.Therefore, research Ligusticum wallichii alkoxide derivative is promptly repaired and protection the propagation of VECs, is the new way of this class disease of control.
Method: detect cytoactive by tetrazolium bromide (MTT) colorimetry, observe Ligustrazine and alkoxide derivative thereof to testing the effect of used human fetal huve cell (HUVECs).After in containing the DMEM nutrient solution of 5% calf serum, cultivating 24h, add the different concns drug solution, continue to cultivate 24h, every then hole adds 20 μ l MTT solution (5mg/ml), cultivate 4h for 37 ℃, the supernatant of inclining, every hole adds dimethyl sulfoxide (DMSO) 100 μ l, vibrated several minutes, on the inherent full-automatic microplate reader of 30min in the mensuration absorbance (A of 570nm place
570nm), be calculated as follows cell proliferation rate P (%).
P(％)＝A-A
0/A
0×100
(A-experimental group absorbancy, A
0-control group absorbancy) the maximum proliferation rate and the activity of compound see Table 2.
The maximum proliferation rate Pmax (%) of table 2 Ligustrazine and alkoxide derivative thereof and activity C (mmol.L
-1) No. Pmax (%) C (mmol.L
-1) No. Pmax (%) C (mmol.L
-1) Va 88.57 0.1 Vk 71.95 0.1Vb 70.88 0.1 Vl 66.04 0.1Vc 83.87 0.1 Vm 52.95 0.1Vd 87.85 0.1 Vn 45.80 0.1Ve 37.00 0.6 Vo 32.10 0.6Vf 76.11 0.1 Vp 59.33 0.1Vg 80.54 0.1 Vq 82.55 0.1Vh 77.32 0.6 Vu 69.39 0.6Vi 75.40 0.1 TMP 20.66 0.6Vj 70.16 0.1 HOTP 28.03 0.6TMP-ligustrazines; HOTP-2-hydroxyl Ligustrazine
As can be seen from Table 2, positive control medicine Ligustrazine is at 0.6mmol.L
-1Shi Zuoyong is the strongest, and proliferation rate is 20.66%.2-methylol-3,5, the 6-trimethylpyrazine is at 0.6mmol.L
-1Shi Zuoyong is the strongest, and proliferation rate is 28.03%.Most of target compounds can promote the propagation of normal HUVECs.
The maximum proliferation rate of introducing four compound Va～Vd of active drug group is respectively 88.57%, 70.88%, 83.87%, 87.85% all greater than Ligustrazine and 2-methylol-3,5, the 6-trimethylpyrazine, and to reach the best use of desired concn be 0.1mmol.L
-1, the activity that these four compounds are described is greater than Ligustrazine and 2-methylol-3,5,6-trimethylpyrazine.
Wherein, Va, Vc are at 0.1～1.5mmol.L
-1All can increase the A of normal HUVECs in the scope
570nmValue, proliferation rate is concentration dependent and successively decreases.Vb is at 0.l～0.6mmol.L
-1Can significantly increase the A of HUVECs
570nmValue.(2) Ligusticum wallichii alkoxide derivative is to the provide protection of the Human umbilical vein endothelial cells of damage.
Data shows that there is the damage of vascular endothelial cell (VECs) in the atherosclerotic, and outstanding behaviours is the increase of the endotheliocyte that comes off in the blood circulation, referring to woods Rong, Liu Juntian etc., Chinese J Pharmacol Toxicol, 2000,14:425.Ligusticum wallichii alkoxide derivative is to H
2O
2The provide protection of HUVECs of damage, the reparation during to the damage of VECs keeps the formation level and smooth, complete, pre-preventing thrombosis of vessel wall to have great importance.
After adding different concns medicine cultivation 24h, adding final concentration is 75 μ mol.L
-1H
2O
2The solution damaging cells.Test method is the same.Ligustrazine and alkoxide derivative thereof see Table 3 to damage HUVECs provide protection (proliferation rate).Table 3 Ligustrazine and alkoxide derivative thereof are to the HUVECs provide protection No. compound concentrations (mmol.L of damage
-1)
0 0.1 0.3 0.6 1.2 1.5Va-49.8-46.7-36.4-13.9-12.0 3.79Vb-45.0-34.2-46.4-53.8-63.4-Vc-49.8-43.2-76.7-79.7-6 0.6-15.6Vd-49.8-51.2-40.4-72.3-83.4-69.0Vf-45.0-29.1-24. 4-12.2,6.01 4.43Vg-45.0-29.7-23.5-11.5,5.62 5.70Vi-45.0-37.6-33.3-21.2-25.1-28.5Vq-45.0-40.5-28.6-28 .3-2.46-1.20TMP-49.8-48.7-47.5-41.0-44.2-HOTP-49.8-43.6-40.5-38.2-36.4-35.8 TMP-ligustrazines; HOTP-2-hydroxyl Ligustrazine
By table 3 result as can be seen, 75 μ mol.L
-1H
2O
2Obviously suppress HUVECs propagation, and Ligustrazine and derivative thereof (Va, Vb, Vc, Vd, Vf, Vg, Vi, Vq) can alleviate the propagation inhibition that causes, cell concentration is more than only adding H
2O
2Control group, illustrate they to the damage HUVECs have provide protection.Wherein Va, Vf, Vg, Vi, Vq strengthen the provide protection of damaging cells with the increase of concentration concentration dependent, and Va, Vf, Vg reach 1.2mmol.L in concentration
-1Hourly growth rate is near the normal control group.(3) the endothelin receptor competition is in conjunction with experiment
Endothelin has strong and persistent vasoconstriction effect external to various myocardium vessels.Receptor antagonist has the positive therapeutic effect to cardiovascular and cerebrovascular diseases clinically.
Experimental technique: with the positive contrast of endothelin-receptor antagonists Bosentan,
125The I endothelin-1 is the receptor competition wedding agent, cultivates with the rat ventricular myocytes theca cell, measures the competition of Ligusticum wallichii alkoxide derivative in conjunction with inhibiting rate.
The result: Ligusticum wallichii alkoxide derivative Vb, Vg, Vk present the effect of endothelin-receptor antagonists to a certain degree, are respectively in conjunction with inhibiting rate: 38.35%, 34.64% and 16.9%.
Activity research shows that Ligusticum wallichii alcohol has the similar activity of Ligustrazine, and therefore according to principle of pro-drug, with Ligustrazine meta-bolites 2-methylol-3,5, the 6-trimethylpyrazine is that lead compound carries out structural modification and transformation, is a kind of effective way that new drug is found.
(4) embodiment embodiment 1. 2-methylols-3,5, the preparation of 6-trimethylpyrazine intermediate
With Tetramethylpyrazine trihydrate (30.4g, 160mmol), Glacial acetic acid (40ml) and 30% hydrogen peroxide (18ml, mixture 220mmol), in 70～80 ℃ of reacting by heating 4 hours, replenish adding 30% hydrogen peroxide 40ml, continue reaction 4 hours, to reacting completely; After being chilled to room temperature, regulate PH=10, chloroform extraction, anhydrous Na with 50% sodium hydroxide solution
2SO
4Drying is filtered, and boils off solvent, obtains Ligustrazine list oxynitrides crude product; Add aceticanhydride 54ml then, reflux 2.5 hours, TLC monitoring removes excessive aceticanhydride under reduced pressure after react completely, and obtains black pulpous state Ligustrazine acetylate; After the cooling, add 100ml, 20% sodium hydroxide solution, placement is spent the night, ethyl acetate extraction (30ml * 5), anhydrous Na
2SO
4Drying is filtered, and removes solvent under reduced pressure, with sherwood oil (30-60 ℃) recrystallization, obtains 2-methylol-3,5, the yellow needle crystal of 6-trimethylpyrazine intermediate, and 15.5g, productive rate are 64%, mp:88～89 ℃.Embodiment 2. 2-nicotinoyl oxygen methyl-3,5, the preparation of 6-trimethylpyrazine (Va)
2-methylol-3 with embodiment 1 preparation, 5,6-trimethylpyrazine intermediate 3mmol, nicotinic acid 6mmol and N, N dimethylamine yl pyridines (DMAP) 0.6mmol mixes, and places the 50ml round-bottomed flask, adds the 10ml pyridine, after the thing dissolving to be mixed, add DCC6mmol, white precipitate DCU occurs, stirring at room 24 hours.After the TLC monitoring reaction reaches balance, stopped reaction, filter and remove white DCU precipitation, filtrate adds 2.5g silica gel evaporated under reduced pressure, rapid column chromatography separates, and eluent is a hexanaphthene: ethyl acetate=1: 5 weight ratio, the heavy crystal of normal hexane get 2-nicotinoyl oxygen methyl-3,5,6-trimethylpyrazine crystallization 0.51g.Productive rate 67.0%.mp：68～70℃。
Spectral analysis data:
1HNMR (CDCl
3): δ (ppm): 9.223～7.359 (m, 4H, Ar-H), 5.451 (s, 2H, CH
2), 2.583 (s, 3H, 6-CH
3), 2.525 (s, 3H, 5-CH
3), 2.471 (s, 3H, 3-CH
3) .IR (cm
-1, the KBr compressing tablet): 3085,3068,3044 (v
CH, pyridine ring), 2983,2949,2854 (v
CH), 1706 (v
C=O), 1587,1416 (v
C=C, the aromatic ring frame vibration), 1276,1144 (v
C-O-C), 745 (γ Ar-H); MS (m/z): M+1:258.Embodiment 3. 2-acetyl asafoetide acyl-oxygen methyl-3,5, the preparation of 6-trimethylpyrazine (Vc)
As embodiment 2 described methods, different is 2-methylol-3,5,6-trimethylpyrazine intermediate 4mmol, acetyl forulic acid 7mmol and N, N dimethylamine yl pyridines (DMAP) 0.8mmol mixes, and eluent is a hexanaphthene: ethyl acetate=1: 2 weight ratio, the tetracol phenixin recrystallization, obtain faint yellow solid 0.48g, productive rate: 43.6%, mp:82～85 ℃.
Spectral analysis data: IR (cm
-1, the KBr compressing tablet): 3326 (v
NH), 2923,2850 (v
CH), 1762,1700 (v
C=O), 1629,1509,1423 (v
C=C), 1274,1218 (v
C-O-C, CH
2OCO), 1235,1155 (v
C-O-C, Ar-O-CH
3), 978 (γ
=CH), 854,838 (γ Φ
H); MS (m/z): M+1:371 embodiment 4. 2-acetyl bigcatkin willow acyl-oxygen methyl-3,5, the preparation of 6-trimethylpyrazine (Vb)
The intermediate of embodiment 1 preparation, press the 2. synthetic ester of chloride method of method:
Acetylsalicylic acid 8mmol is in the 100ml three-necked flask, and dripping thionyl chloride 0.8ml and pyridine are 1 under the condition of ice bath, finish, and remove ice bath, slowly heats up back flow reaction 2.5 hours.TLC monitoring is after react completely, and cooling removes excessive sulfur oxychloride under reduced pressure, and residue adds the 15ml tetrahydrofuran (THF) and fully stirs, and obtains the tetrahydrofuran solution of acetylsalicylic acid acyl chlorides.Under condition of ice bath, above-mentioned organic carboxyl acid solution of acid chloride dropwise joined contain 2-methylol-3,5, in the tetrahydrofuran solution of 6-trimethylpyrazine and pyridine, remove ice bath, heating reflux reaction 3h.TLC monitoring is after react completely, and cooling removes by filter pyridinium salt, and filtrate decompression is steamed and removed tetrahydrofuran (THF), dark-brown oily matter, rapid column chromatography separates, eluent is a hexanaphthene: ethyl acetate=1: 1, oily product 0.6g.Cyclohexane/ethyl acetate (3: 1) recrystallization gets white solid 2-acetyl bigcatkin willow acyl-oxygen methyl-3,5,6-trimethylpyrazine, productive rate 45.7%.
Spectral analysis data:
1HNMR (CDCl
3): δ (ppm): 7.583～6.939 (m, 4H, Ar-H), 5.379 (s, 2H, CH
2), 2.561 (s, 3H, 6-CH
3), 2.524 (s, 3H, 5-CH
3), 2.507 (s, 3H, CH
3COO-Ar), 2.309 (s, 3H, 3-CH
3) .IR (cm
-1, coating): 2991,2952,2923 (v
CH), 1753 (v
C=O), 1615,1469 (vC=C, Φ
H), 1308,1253 (v
C-O-C), 762 (γ Φ
H). embodiment 5.2-Chinese cassia tree acyl-oxygen methyl-3,5, the preparation of 6-trimethylpyrazine (Vh)
As embodiment 4 described preparation methods, styracin 8mmol obtains faint yellow oily product 1.07g, productive rate: 63%.
Spectral analysis data:
1HNMR (CDCl
3): δ (ppm): 7.62 (d, 1H, J=40Hz, Ar-CH=), 7.44～7.20 (m, 5H, Ar-H), 6.38 (d, 1H, J=40Hz ,=CH-CO), 5.22 (s, 2H, CH
2), 2.48 (s, 3H, 6-CH
3), 2.40 (s, 6H, 5,6-CH
3) .IR (KBr compressing tablet, cm
-1): 3028,2990,2953,2923 (v
CH), 1713 (v
C=O), 1637 (v
C=C), 1497,1416 (v
C=C, Φ
H), 1163 (v
C-O-C), 987 (γ
=CH), 768 (γ Φ
H). embodiment 6. 2-are to chlorobenzene oxygen isobutyl acyl-oxygen methyl-3,5,6 ,-trimethylpyrazine (Vd)
As embodiment 4 described preparation methods, clofibric acid 8mmol, eluent: hexanaphthene: ethyl acetate=4: 1 obtains oily product 0.67g, productive rate: 64.9%.
Spectral analysis data:
1HNMR (CDCl
3): δ (ppm): 7.111 (d, 2H, J=8.7Hz C2 '-H, C6 '-H), 6.759 (d, 2H, J=9.0Hz C3 '-H, C5 '-H), 5.257 (s, 2H, CH
2), 2.491 (s, 3H, 6-CH
3), 2.452 (s, 3H, 5-CH
3), 2.408 (s, 3H, 3-CH
3), 1.603 (s, 6H, CH
3-C-CH
3).IR (cm
-1Coating): 2992,2939,2924,2857 (v
CH), 1739 (v
C=O), 1594,1489 (v
C=C, the aromatic ring frame vibration), 1282,1093 (v
C-O-C, CH
2OCO), 1238,1139 (v
C-O-C, CO-Ar), 788 (v
C-Cl) embodiment 7. 2-(2,4-dimethoxy Chinese cassia tree acyl-oxygen methyl)-3,5,6-trimethylpyrazine (Vj)
As embodiment 4 described preparation methods, 2,4-dimethoxy-cinnamic acid 8mmol, eluent: hexanaphthene: ethyl acetate=1: 3, behind the recrystallization faint yellow solid 0.59g, productive rate: 58.3%, mp:83～85 ℃.
Spectral analysis data:
1HNMR (CDCl
3): δ (ppm): 7.933 (d, 1H, Ar-CH=, J=15.9Hz), 7.427～6.427 (m, 3H, Ar-H), 6.488 (d, 1H ,=CH-CO, J=13.2Hz), 5.305 (s, 2H, CH
2), 3.835 (s, 6H ,-OCH
3), 2.574 (s, 3H, 6-CH
3), 2.515 (s, 6H, 5,6-CH
3); IR (KBr, compressing tablet cm
-1): 2989,2972,2942,2839 (v
CH), 1705 (v
C=O), 1614 (v
C=C), 1505,1411 (v
C=C, Φ
H), 1264,1180 (v
C-O-C, CH
2OCO), 1248,1217,1161,1122, (v
C-O-C, Ar-O-CH
3), 1035 (γ
=CH), 820 (γ Φ
H); MS (m/z): M+1:343.
Claims (10)
1. Ligusticum wallichii alkoxide derivative is characterized in that, has following general structure:
Wherein R is phenyl, monosubstituted phenyl or polysubstituted phenyl; Benzyl, the single replacement or polysubstituted benzyl; Styroyl, the single replacement or polysubstituted styroyl; Styryl, the single replacement or polysubstituted styryl; The substituted benzene oxygen ethyl; Five-membered ring or substituted five-membered heterocycle, hexa-member heterocycle or replacement hexa-member heterocycle; Amino acid based.
2. above-mentioned Ligusticum wallichii alkoxide derivative as claimed in claim 1 is characterized in that described heterocycle is meant fat or aromatic heterocycle.
3. the preparation method of the described Ligusticum wallichii alkoxide of claim 1 derivative; comprise methylol-3 with intermediate 2-; 5; 6-trimethylpyrazine and organic carboxyl acid are at N; the inferior uride dehydration synthesis method of dicyclohexyl under the catalysis of N dimethylamine yl pyridines or by organic carboxyl acid and sulfur oxychloride being made the acidylate synthesis method under pyridine alkalescence behind the acyl chlorides is separated and/or the recrystallization purifying acquisition then.
4. as the preparation method of Ligusticum wallichii alkoxide derivative as described in the claim 3, it is characterized in that, intermediate 2-methylol-3,5, the preparation of 6-trimethylpyrazine comprises the steps:
(1) Tetramethylpyrazine trihydrate, Glacial acetic acid and 30% hydrogen peroxide were mixed by weight 3: 4: 1.5, in 70～80 ℃ of reacting by heating 4～5 hours, add 30% hydrogen peroxide of equivalent, continue reaction 4～5 hours, the thin-layer chromatography monitoring is cooled to room temperature to reacting completely;
(2) regulate PH=10, chloroform extraction, anhydrous Na with 45%～60% sodium hydroxide solution
2SO
4Drying is filtered, and boils off trichloromethane, obtains Ligustrazine list oxynitrides crude product;
(3) add aceticanhydride then, reflux 2～3 hours, TLC monitoring removes excessive aceticanhydride under reduced pressure after react completely, and obtains black pulpous state Ligustrazine acetylate;
(4) the cooling back adds 20%～30% sodium hydroxide solution, places ethyl acetate extraction, anhydrous Na 10～20 hours
2SO
4Drying is filtered, and removes solvent under reduced pressure, obtains 2-methylol-3,5,6-trimethylpyrazine (IV) intermediate;
(5), get yellow needle crystal with sherwood oil 30-60 ℃ recrystallization.
5. the preparation method of Ligusticum wallichii alkoxide derivative as claimed in claim 3 is characterized in that, synthesizes with the inferior uride evaporation of dicyclohexyl:
With above-mentioned 2-methylol-3,5,6-trimethylpyrazine intermediate, organic carboxyl acid and N, the N dimethylamine yl pyridines is pressed mmole than 1～2: 2～4: 0.1～0.2 mixes, add 10～15ml pyridine, dissolving adds the inferior uride of dicyclohexyl and equates the mmole amount with organic carboxyl acid, the white precipitate dicyclohexylurea (DCU) appears, stirring at room 20～30 hours, after reaction reaches balance, stopped reaction, filter and remove white precipitate, filtrate adds 2～3g silica gel evaporated under reduced pressure.
6. the preparation method of Ligusticum wallichii alkoxide derivative as claimed in claim 3 is characterized in that, and is synthetic with chloride method:
Dripping thionyl chloride 0.8～0.9m1 and pyridine 0.25ml under organic carboxyl acid 8～9mmol condition of ice bath, remove ice bath, be warming up to and boil, back flow reaction 2～3 hours is after reacting completely, cooling, remove excessive sulfur oxychloride under reduced pressure, residue adds 12～16ml tetrahydrofuran (THF) and fully stirs, and obtains the tetrahydrofuran solution of organic carboxyl acid acyl chlorides, under condition of ice bath, above-mentioned organic carboxyl acid solution of acid chloride joined contain 2-methylol-3,5, in the tetrahydrofuran solution of 6-trimethylpyrazine and pyridine, remove ice bath, heating reflux reaction 3～4 hours, after reacting completely, cooling, remove by filter pyridinium salt, filtrate decompression is steamed and is removed tetrahydrofuran (THF).
7. the preparation method of Ligusticum wallichii alkoxide derivative as claimed in claim 3 is characterized in that, described organic carboxyl acid is: phenylformic acid, the single replacement or polysubstituted phenylformic acid; Toluylic acid, the single replacement or polysubstituted toluylic acid; Phenylpropionic acid, the single replacement or polysubstituted benzo acid; Styracin or various substituted cinnamic acid; Bezalip Tablets or various substituted benzene oxygen isopropylformic acid; Each seed amino acid; Various alicyclic heterocyclics or fragrant heterocyclic carboxylic acid and various replacement alicyclic heterocyclic or fragrant heterocyclic carboxylic acid.
8. the preparation method of Ligusticum wallichii alkoxide derivative as claimed in claim 3 is characterized in that, described separation is that rapid column chromatography separates, and eluting solvent is a cyclohexane/ethyl acetate.
9. pharmaceutical composition contains the Ligusticum wallichii alkoxide derivative of claim 1, and Ligusticum wallichii alkoxide derivative and auxiliary material be mixed routinely, makes the medicine of different dosage form according to a conventional method.
10. the application of the described rhizome of chuanxiong alkoxide of claim 9 derivatives medicinal composition is used for the reparation and protection medicine of vascular endothelial cell, or endothelin-receptor antagonists.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB02135989XA CN1184209C (en) | 2002-12-20 | 2002-12-20 | Chuanxiong alkoxide derivative and its preparation and medicinal composition containing it and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB02135989XA CN1184209C (en) | 2002-12-20 | 2002-12-20 | Chuanxiong alkoxide derivative and its preparation and medicinal composition containing it and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1424313A true CN1424313A (en) | 2003-06-18 |
| CN1184209C CN1184209C (en) | 2005-01-12 |
Family
ID=4748458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB02135989XA Expired - Fee Related CN1184209C (en) | 2002-12-20 | 2002-12-20 | Chuanxiong alkoxide derivative and its preparation and medicinal composition containing it and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1184209C (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1296409C (en) * | 2003-10-15 | 2007-01-24 | 北京理工大学 | Ligustrazine polyethleneglycol ester and preparation method thereof |
| CN1326851C (en) * | 2005-12-06 | 2007-07-18 | 山东大学 | Ligustrazine alkyl piperazine derivative, and its preparing method and medicinal composition and use |
| WO2009056070A1 (en) * | 2007-10-26 | 2009-05-07 | Jiaming Li | Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application |
| WO2010034212A1 (en) * | 2008-09-28 | 2010-04-01 | 安徽省新星药物开发有限责任公司 | Phenoxy acetic acid pyrazine ester derivatives, the preparation methods and uses thereof |
| CN101786992A (en) * | 2010-03-10 | 2010-07-28 | 天津市汉康医药生物技术有限公司 | 2-hydroxymethyl-3,5,6-trimethylpyrazine derivatives, preparation methods and application thereof |
| CN102786484A (en) * | 2012-08-20 | 2012-11-21 | 山东大学 | Tetramethylpyrazine formyloxy cinnamic acid derivative and preparation method and application thereof |
| CN103864768A (en) * | 2014-03-04 | 2014-06-18 | 广西师范大学 | Ligustrazine stilbene derivatives as well as preparation method and application thereof |
| CN103936758A (en) * | 2014-02-21 | 2014-07-23 | 温州医科大学 | Biotin labeled ligustrazine and preparation method thereof |
| CN106928155A (en) * | 2017-01-20 | 2017-07-07 | 贵州医科大学 | Ligustrazine butylphenyl phthaleine split class compound and preparation method thereof and the application in medicine |
| CN106977464A (en) * | 2016-01-15 | 2017-07-25 | 雷海民 | Ligustrazine substituted cinnamic acid analog derivative (LQC-W) and its application with neuroprotective activity |
| JP2018520168A (en) * | 2015-07-07 | 2018-07-26 | グゥアンヂョウ マグパイ ファーマシューティカルズ カンパニー リミテッド | New pyrazine derivatives, their preparation and pharmaceutical applications |
| CN109988153A (en) * | 2017-12-29 | 2019-07-09 | 深圳夏浠湾医药科技有限公司 | A kind of ligustrazine derivant and its preparation method and application |
| CN111789844A (en) * | 2020-07-31 | 2020-10-20 | 深圳市橄榄生物医药科技有限公司 | Application of pyrazine compound in preparation of medicine |
| CN112961143A (en) * | 2021-02-04 | 2021-06-15 | 河南省人民医院 | Ligustrazine derivative and preparation method thereof |
-
2002
- 2002-12-20 CN CNB02135989XA patent/CN1184209C/en not_active Expired - Fee Related
Cited By (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1296409C (en) * | 2003-10-15 | 2007-01-24 | 北京理工大学 | Ligustrazine polyethleneglycol ester and preparation method thereof |
| CN1326851C (en) * | 2005-12-06 | 2007-07-18 | 山东大学 | Ligustrazine alkyl piperazine derivative, and its preparing method and medicinal composition and use |
| US8350033B2 (en) | 2007-10-26 | 2013-01-08 | Jiaming Li | 4-((3, 5, 6-trimethylpyrazine-2-yl) methoxyl) benzoic acid and its derivatives |
| WO2009056070A1 (en) * | 2007-10-26 | 2009-05-07 | Jiaming Li | Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application |
| WO2010034212A1 (en) * | 2008-09-28 | 2010-04-01 | 安徽省新星药物开发有限责任公司 | Phenoxy acetic acid pyrazine ester derivatives, the preparation methods and uses thereof |
| CN101684102B (en) * | 2008-09-28 | 2013-06-05 | 安徽省新星药物开发有限责任公司 | Phenoxyacetic acid ester pyrazine derivative as well as preparation method and applications thereof |
| CN101786992A (en) * | 2010-03-10 | 2010-07-28 | 天津市汉康医药生物技术有限公司 | 2-hydroxymethyl-3,5,6-trimethylpyrazine derivatives, preparation methods and application thereof |
| CN101786992B (en) * | 2010-03-10 | 2012-11-07 | 天津市汉康医药生物技术有限公司 | 2-hydroxymethyl-3,5,6-trimethylpyrazine derivatives, preparation methods and application thereof |
| CN102786484A (en) * | 2012-08-20 | 2012-11-21 | 山东大学 | Tetramethylpyrazine formyloxy cinnamic acid derivative and preparation method and application thereof |
| CN102786484B (en) * | 2012-08-20 | 2015-11-18 | 山东大学 | Ligustrazine methanoyl cinnamic acid derivative and preparation method thereof and application |
| CN103936758A (en) * | 2014-02-21 | 2014-07-23 | 温州医科大学 | Biotin labeled ligustrazine and preparation method thereof |
| CN103864768A (en) * | 2014-03-04 | 2014-06-18 | 广西师范大学 | Ligustrazine stilbene derivatives as well as preparation method and application thereof |
| CN103864768B (en) * | 2014-03-04 | 2016-04-06 | 广西师范大学 | Ligustrazine stilbenoids derivatives and preparation method thereof and application |
| IL256744B2 (en) * | 2015-07-07 | 2023-04-01 | Guangzhou Magpie Pharmaceuticals Co Ltd | Pyrazine derivatives, and preparation method and medical application thereof |
| JP7067792B2 (en) | 2015-07-07 | 2022-05-16 | グゥアンヂョウ マグパイ ファーマシューティカルズ カンパニー リミテッド | New pyrazine derivative, its preparation method and pharmaceutical application |
| JP2018520168A (en) * | 2015-07-07 | 2018-07-26 | グゥアンヂョウ マグパイ ファーマシューティカルズ カンパニー リミテッド | New pyrazine derivatives, their preparation and pharmaceutical applications |
| EP3321259A4 (en) * | 2015-07-07 | 2019-03-27 | Guangzhou Magpie Pharmaceutical Co., Ltd. | New pyrazine derivative, and preparation method and medical application thereof |
| IL256744B (en) * | 2015-07-07 | 2022-12-01 | Guangzhou Magpie Pharmaceuticals Co Ltd | Pyrazine derivatives, and preparation method and medical application thereof |
| CN106977464A (en) * | 2016-01-15 | 2017-07-25 | 雷海民 | Ligustrazine substituted cinnamic acid analog derivative (LQC-W) and its application with neuroprotective activity |
| CN106977464B (en) * | 2016-01-15 | 2019-12-10 | 雷海民 | Ligustrazine substituted cinnamic acid derivative (LQC-W) with neuroprotective activity and application thereof |
| CN106928155B (en) * | 2017-01-20 | 2021-07-16 | 贵州医科大学 | Ligustrazine-butylphthalide split compound, preparation method thereof and application thereof in medicines |
| CN106928155A (en) * | 2017-01-20 | 2017-07-07 | 贵州医科大学 | Ligustrazine butylphenyl phthaleine split class compound and preparation method thereof and the application in medicine |
| CN109988153B (en) * | 2017-12-29 | 2021-11-19 | 深圳夏浠湾医药科技有限公司 | Ligustrazine derivative and preparation method and application thereof |
| CN109988153A (en) * | 2017-12-29 | 2019-07-09 | 深圳夏浠湾医药科技有限公司 | A kind of ligustrazine derivant and its preparation method and application |
| CN111789844A (en) * | 2020-07-31 | 2020-10-20 | 深圳市橄榄生物医药科技有限公司 | Application of pyrazine compound in preparation of medicine |
| CN111789844B (en) * | 2020-07-31 | 2022-03-11 | 深圳市橄榄生物医药科技有限公司 | Application of pyrazine compound in preparation of medicine |
| CN112961143A (en) * | 2021-02-04 | 2021-06-15 | 河南省人民医院 | Ligustrazine derivative and preparation method thereof |
| CN112961143B (en) * | 2021-02-04 | 2023-11-07 | 河南省人民医院 | Ligustrazine derivative and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1184209C (en) | 2005-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69725293T2 (en) | N- (2 OXOACETYL OR SULPHONYL) -PYRROLIDINE / PIPERIDINE-2-CARBONIC ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY | |
| CN1424313A (en) | Chuanxiong alkoxide derivative and its preparation and medicinal composition containing it and use thereof | |
| CN108299458B (en) | Oridonin derivative and preparation method and application thereof | |
| CN112592331B (en) | Oseltamivir PROTAC compound, preparation method thereof and application thereof in anti-influenza virus drugs | |
| CN105777632A (en) | Aromatic-ring azacyclo derivatives and application thereof | |
| CN103113386B (en) | Nitrogen heterocyclic substituted-dihydro artemisinin derivative and application thereof | |
| US20030087949A1 (en) | Indolylpyrrole derivatives and cell death inhibitors | |
| EP1224932A1 (en) | Drugs inhibiting cell death | |
| CN110028546B (en) | Cyclopentane-polyhydrophenanthrene framework compound with function of regulating blood coagulation factor VIII level to play anti-tumor role and application thereof | |
| US6589977B1 (en) | Pyrrole derivatives and cell death inhibitors | |
| DE60318567T2 (en) | PIPERAZINBENZOTHIAZOLE AS ACTIVE AGENTS IN THE TREATMENT OF ISMARIANS AND DISEASES OF THE CNS SYSTEM | |
| CN103183682A (en) | C-10 site carbamido substituted artemisinin derivative, preparation method and application | |
| CN102010420A (en) | [(10S)-9,10-dihydroartemisinine-10-oxyl]benzaldehyde semicarbazones (sulfur) series substances as well as preparation method and application thereof | |
| CN113912594B (en) | Nitrothiophene methylamine optical isomer and medical application thereof | |
| CN111718325A (en) | 2,4, 5-substituted pyrimidine compound and preparation method and application thereof | |
| CN102753166B (en) | Tetrapeptide analogs, preparation method and use thereof | |
| CN111574582B (en) | Tripterine derivative and preparation method and application thereof | |
| CN115246869A (en) | Tripterine-thiazolidinedione derivative as well as preparation method and application thereof | |
| CN102443005A (en) | Spiroheterocycle compound of chalcone and application of spiroheterocycle compound | |
| EP2776017B1 (en) | Gold compounds having alkynyl ligands and therapeutic use thereof | |
| CN113105391B (en) | Lappaconitine derivative with analgesic activity and preparation method and application thereof | |
| CN103304556B (en) | Schiff bases compounds containing chromene, Preparation Method And The Use | |
| CN116655510A (en) | Pyrrolidine compound and preparation method and application thereof | |
| CN106608824A (en) | Aromatic acid ester compound and preparation method and application thereof | |
| CN106389419A (en) | Application of arylhydrazide compound in treatment of acute myocardial ischemic coronary heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zheng Huaqing Document name: Notice of conformity |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050112 Termination date: 20151220 |
|
| EXPY | Termination of patent right or utility model |